Phase I Study of BCMA CAR-T using instant manufacturing platform or traditional production process for relapsed/refractory multiple myeloma therapy

被引：0
|
作者：
Liu, Hui [1 ]
Wang, Ting [1 ]
Yang, Yazi [1 ]
Feng, Ru [1 ]
Li, Jiangtao [1 ]
Zhang, Chunli [1 ]
Bai, Jiefei [1 ]
Ding, Yanping [2 ]
Liu, Guanghua [2 ]
Wu, Fei [2 ]
Lu, Xinan [2 ]
He, Ting [2 ]
机构：
[1] Beijing Hosp, Beijing, Peoples R China
[2] Beijing Imunopharm Technol Co Ltd, Beijing, Peoples R China
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA-07
引用
收藏
页码：S5 / S5
页数：1
相关论文
共 50 条
  • [21] Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma.
    Liu, Yarong
    Chen, Zhi
    Wei, Runhong
    Shi, Lin
    He, Feng
    Shi, Zixiao
    Jin, Tao
    Xie, Ronglin
    Wei, Baofeng
    Chen, Jing
    Fang, Hongliang
    Zhu, Bo
    Li, Qi-Jing
    Wang, Pin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
    Qingming Wang
    Runhong Wei
    Shufang Guo
    Chao Min
    Xiong Zhong
    Hui Huang
    Zhi Cheng
    Cancer Gene Therapy, 2024, 31 : 420 - 426
  • [23] Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform
    Sperling, Adam S.
    Nikiforow, Sarah
    Nadeem, Omar
    Mo, Clifton C.
    Laubach, Jacob P.
    Anderson, Kenneth C.
    Alonso, Alejandro
    Ikegawa, Shuntaro
    Prabhala, Rao
    Rodriguez, Diego Hernandez
    Daley, Heather
    Shaw, Kit L.
    Arihara, Yohei
    Ansari, Soudeh
    Quinn, David S.
    Pearson, David
    Hack, Anniesha
    Treanor, Louise M.
    Bu, Dexiu
    Mataraza, Jennifer
    Rispoli, Lawrence
    Credi, Marc
    Ritz, Jerome
    De Vita, Serena
    Munshi, Nikhil C.
    BLOOD, 2021, 138 : 3864 - +
  • [24] Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma
    Martin, Thomas G.
    Madduri, Deepu
    Pacaud, Lida
    Usmani, Saad Z.
    FUTURE ONCOLOGY, 2023, 19 (34) : 2297 - 2311
  • [25] Phase II Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/ Refractory Multiple Myeloma
    Chen, Wenming
    Fu, Chengcheng
    Fang, Baijun
    Liang, Aibin
    Xia, Zhongjun
    He, Yanjuan
    Lu, Jin
    Liu, Hui
    Hou, Ming
    Cai, Zhen
    Yang, Wei
    Hao, Siguo
    Jiang, Songfu
    Jing, Hongmei
    Liu, Jing
    Du, Xin
    Fu, Rong
    Mei, Heng
    Zhu, Zunmin
    Yang, Yanli
    Liu, Hong
    Yuan, Daijing
    Zhao, Hongxia
    Xiao, Jun
    Wang, Wei
    Wang, Huamao
    Li, Zonghai
    BLOOD, 2022, 140 : 4564 - 4565
  • [26] Improved efficacy and safety of a dual-target CAR-T cell therapy targeting BCMA and CD38 for relapsed/refractory multiple myeloma from a phase I study
    Li, C.
    Mei, H.
    Hu, Y.
    Guo, T.
    Liu, L.
    Jiang, H.
    Tang, L.
    Wu, Y.
    Ai, L.
    Deng, J.
    Jin, D.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1723 - 1724
  • [27] Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
    Chenggong Li
    Jia Xu
    Wenjing Luo
    Danying Liao
    Wei Xie
    Qiuzhe Wei
    Yinqiang Zhang
    Xindi Wang
    Zhuolin Wu
    Yun Kang
    Jin’e Zheng
    Wei Xiong
    Jun Deng
    Yu Hu
    Heng Mei
    Leukemia, 2024, 38 : 149 - 159
  • [28] Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
    Lu Han
    Ji-Shuai Zhang
    Jian Zhou
    Ke-Shu Zhou
    Ben-Ling Xu
    Lin-Lin Li
    Bai-Jun Fang
    Qing-Song Yin
    Xing-Hu Zhu
    Hu Zhou
    Xu-Dong Wei
    Hong-Chang Su
    Bing-Xiang Zhang
    Ya-Nan Wang
    Bin Xiang
    Quan-Li Gao
    Yong-Ping Song
    Leukemia, 2021, 35 : 3002 - 3006
  • [29] Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
    Li, Chenggong
    Xu, Jia
    Luo, Wenjing
    Liao, Danying
    Xie, Wei
    Wei, Qiuzhe
    Zhang, Yinqiang
    Wang, Xindi
    Wu, Zhuolin
    Kang, Yun
    Zheng, Jin'e
    Xiong, Wei
    Deng, Jun
    Hu, Yu
    Mei, Heng
    LEUKEMIA, 2024, 38 (01) : 149 - 159
  • [30] High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
    Yuanyan Tang
    Haisen Yin
    Xinying Zhao
    Dan Jin
    Yan Liang
    Tao Xiong
    Lu Li
    Wen Tang
    Jiangzhao Zhang
    Min Liu
    Zhuojun Yu
    Huimin Liu
    Sibin Zang
    Zhiping Huang
    Journal of Experimental & Clinical Cancer Research, 41
12345